What is Synthace?
Synthace, headquartered in London, UK, and Boston, US, is at the forefront of computer-aided biology. Their proprietary cloud software platform, Antha, is designed to empower biologists by enabling them to program lab automation without requiring traditional coding expertise. The platform features a graphical user interface developed by biologists for biologists, facilitating the automation of entire experimental workflows, from initial planning and execution to data collection and analysis. This innovative approach aims to streamline and accelerate the pace of biological research and development.
How much funding has Synthace raised?
Synthace has raised a total of $72.1M across 4 funding rounds:
Angel/Seed
$2.1M
Series A
$9.4M
Series B
$25.6M
Series C
$35M
Angel/Seed (2013): $2.1M with participation from Sofinnova Partners
Series A (2017): $9.4M led by Sofinnova Partners, SOSV, Bioeconomy Capital., Amadeus Capital Partners, White Cloud Capital, and 11.2 Capital
Series B (2018): $25.6M supported by Horizons Ventures
Series C (2021): $35M featuring Sofinnova Partners and Horizons Ventures
Key Investors in Synthace
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. They are known for their hands-on approach, acting as company builders across the entire value chain of life sciences investments, from seed to later stages.
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity. They support innovative projects with the potential for transformative change, targeting startups and enterprises in the science and technology sectors.
SOSV
SOSV is a multi-stage venture capital investor that provides both intellectual and financial capital to accelerate the growth of founders' big ideas, with a focus on deep tech and life sciences.
What's next for Synthace?
The recent major enterprise-level funding, including the Series C financing, positions Synthace for significant scaling and further innovation in the computer-aided biology sector. This strategic investment will likely fuel expansion of their platform's capabilities, enhance their market reach, and support continued R&D efforts. The company's focus on enabling biologists to automate complex lab processes suggests a trajectory towards becoming a foundational technology provider for the life sciences industry, potentially leading to further strategic partnerships and market penetration.
See full Synthace company page
